Your cart is currently empty!
Lenvanix (lenvatinib)
Product Description: First new frontline treatment option for HCC approved in Japan Lenvatinib is amultikinase inhibitor that interrupts the pathways of VEGFR1,VEGFR2 and VEGFR3.It is used in the treatment of differentiated thyroid cancer (DTC),renal Cell Carcinoma and Hepatocellular Carcinoma (HCC) Lenvanix(lenvatinib) Product Description: First new frontline treatment option for HCC approved in Japan Lenvatinib is […]
Description
Product Description: First new frontline treatment option for HCC approved in Japan Lenvatinib is amultikinase inhibitor that interrupts the pathways of VEGFR1,VEGFR2 and VEGFR3.It is used in the treatment of differentiated thyroid cancer (DTC),renal Cell Carcinoma and Hepatocellular Carcinoma (HCC) Lenvanix(lenvatinib) Product Description: First new frontline treatment option for HCC approved in Japan Lenvatinib is amultikinase inhibitor that interrupts the pathways of VEGFR1,VEGFR2 and VEGFR3.It is used in the treatment of differentiated thyroid cancer (DTC),renal Cell Carcinoma and Hepatocellular Carcinoma (HCC)Related products
Acatinib 100
Palboxen 125 mg (Palbociclib)
Velpanex 400 mg & 100 mg (Sofosbuvir & Velpatasvir)
Ibrucent 140 mg (Ibrutinib)
Barigen (Baricitinib 4mg) Rx
Reviews
There are no reviews yet.